Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Use of antiparkinsonian medication tied to acquired premature ejaculation

06 Jun 2018

Individuals taking antiparkinsonian drugs have developed ejaculatory dysfunction, which suggests a possible medication effect, in a case series of Parkinson’s disease (PD) patients with acquired premature ejaculation (PE).

The mean age of PD onset was 53.3±12.7 years (range, 38–77 years), while sexual problems started to appear 4.0±3.1 years later. Patients had a mean 7.3 min (range, 2–20 min) of intravaginal ejaculation latency (IELT) before the onset of acquired PE.

Of note, there was an abrupt appearance of the ejaculatory dysfunction as characterized by a dramatically shortened IELT in all patients. Furthermore, three patients had an ejaculation prior to vaginal penetration, which hampered sexual intercourse.

In some patients, two additional sexual problems occurred: four had erectile dysfunction, five had libido changes, four had increase desire and one had reduced desire.

In this study, the investigators described eight PD patients who asked for a sexological consultation between 2008 and 2014 because of new-onset of PE. Patients were diagnosed with acquired PE according to the DSM-V criteria and the International Society for Sexual Medicine committee. Demographic, medical and sexual-related data of patients were retrieved and analysed.

Acquired PE is defined as “a male sexual dysfunction characterized by the development of a clinically significant and bothersome reduction in ejaculation latency time in men with previous normal ejaculatory experiences, often to about 3 minutes or less, the inability to delay ejaculation on all or nearly all vaginal penetrations, and the presence of negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.” [Transl Androl Urol 2016;5:434-449]

“PE has been reported in 40.6–51.5 percent of men affected by PD,” the investigators said. “However, this nonmotor sexual complaint has not been studied in detail.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.